Response to "How Important Is the Assessment of Soluble ACE-2 in COVID-19?"

Am J Hypertens. 2021 Apr 2;34(3):298. doi: 10.1093/ajh/hpaa188.

Authors

Marina Rieder^{1

2}, Christoph Bode^{1

2}, Daniel Duerschmied^{1

2}, Achim Lother^{1

2

3}

Affiliations

¹ Heart Center Freiburg University, Department of Cardiology and Angiology I, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
² Department of Medicine III (Interdisciplinary Medical Intensive Care), Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
³ Institute of Experimental and Clinical Pharmacology and Toxicology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
COVID-19*
Humans
SARS-CoV-2

Substances

Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors